Original Article
CD47 antibody suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy

Yong Li1*, Xuguan Chen1*, Peng Li1, Qianxuan Xiao2, Daorong Hou3, Xiangqing Kong1

1Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, P. R. China; 2Department of Stomatology, Nanjing Medical University, Nanjing 211166, Jiangsu Province, P. R. China; 3Key Laboratory of Model Animal Research, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing 211166, Jiangsu Province, P. R. China. *Equal contributors.

Received November 4, 2019; Accepted June 2, 2020; Epub September 15, 2020; Published September 30, 2020

Abstract: In this study, we investigated whether CD47 antibody could attenuate isoproterenol (ISO)-induced cardiac hypertrophy in mice and H9C2 cells. Cardiac hypertrophy was induced by intraperitoneal (i.p.) injection of ISO (60 mg.kg−1.d−1 in 100 µl of sterile normal saline) daily for 14 days, and cell hypertrophy was induced by ISO (10−5 mol/l) for 48 h. The injury was confirmed by increased levels of lactate dehydrogenase (LDH) and creatine kinase MB (CK-MB), increased heart-to-body weight (HW/BW) ratio and visible cardiac fibrosis. Apoptosis was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining. Autophagic flux in H9c2 cells was monitored by TEM and mRFP-GFP-LC3 virus transfection. The expression levels of Cleaved caspase-3, Cleaved caspase-9 and autophagy-related proteins were detected by Western blotting. CD47 antibody significantly limited ISO-induced increases in LDH, CK-MB, HW/BW ratio and attenuated cardiac fibrosis, oxidative stress, and apoptosis in the heart; CD47 antibody promoted autophagy flow and decreased cell apoptosis in cardiac tissues. Moreover, autophagy inhibitor chloroquine (CQ) reversed the effect of CD47 antibody treatment. In conclusion, CD47 antibody reduced ISO-induced cardiac hypertrophy by improving autophagy flux and rescuing autophagic clearance.

Keywords: Cardiac hypertrophy, CD47 antibody, oxidative stress, apoptosis, autophagy

Introduction
Cardiac hypertrophy, occurring during the clinical course of stress-induced heart failure [1-3], is characterized by an abnormal enlargement of the heart muscle resulting from increased myocyte cell size and abnormal proliferation of non-muscle cells [4]. Cardiac hypertrophy is controlled by a complex signal transduction and gene regulatory network [5, 6]. Recently, autophagy, a dynamic process involving the bulk degradation of cytoplasmic organelles and proteins, has been proven to participate in the pathogenesis of cardiac hypertrophy [7-12].

Isoproterenol (ISO), a nonselective β-adrenergic receptor (β-AR) agonist, has been widely used as a stimulus for cardiac hypertrophy [13, 14] due to its convenience and rapidity in yielding reproducible results [15]. The pathophysiological and morphological aberrations in the heart of myocardial necrotic rat model are comparable with those in human myocardial infarction [16, 17]. These β-adrenergic effects can result in cardiac “infarct-like” lesions in experimental animals [18], similar to those in patients with myocardial infarction [19]. ISO-induced cardiac hypertrophy is accompanied by a significant decrease in autophagy activity [20-22].

CD47 is a widely expressed cell receptor [23] and activator of NADPH-oxidase-mediated reactive oxygen species (ROS) production in vascular cells [24]. Previous studies have identified the role of CD47 in limiting blood flow [23] and metabolism [25], and suggested the additional benefits by therapeutic targeting of CD47 in myocardial infarction [26]. CD47 transcript has been reported to increase in ventricular biopsies from patients of left ventricular heart failure (LVHF) [27]. CD47-knockout mice displayed protection from transverse aortic constriction (TAC)-driven LVHF with enhanced cardiac functions, decreased cellular hypertrophy and fibro-
CD47 antibody in cardiac hypertrophy

sis [26], and CD47 deficiency conferred cell survival through the activation of autophagic flux against radiation injury [28-30]. Moreover, CD47-blocking antibody has been used in research of various diseases including tumor and atherosclerosis [31-36]. So far, the specific effect of CD47 antibody on ISO-induced cardiac hypertrophy remains unclear. In this study, we investigated the effect of CD47 antibody on cardiac hypertrophy, fibrosis and myocyte apoptosis in mouse and cell models with ISO-induced cardiomyocyte hypertrophy.

Materials and methods

Animals

Eighty C57/BL6 male mice, 8-10 weeks old, weighing 22-28 g, were obtained from Nanjing University. The mice were housed in a Specific Pathogen Free (SPF) facility in the Animal Core Facility of Nanjing Medical University under standard temperature conditions with a 12 h light/dark cycle and fed ad libitum. All experimental protocols and animal handling procedures were performed according to the “Guide for the Care and Use of Laboratory Animals” (National Academic Press, USA, 1996). The animal study was approved by the Institutional Animal Care and Use Committee of the Nanjing Medical University.

Animal model of cardiac hypertrophy

Animal model of cardiac remodeling was established by intraperitoneal injection of ISO (I5627, Sigma-Aldrich, USA; 60 mg.kg\(^{-1}\).d\(^{-1}\), dissolved in sterile normal saline) once daily for 14 consecutive days [37]. The animals were then allowed to recover with free access to food and water. At 24 h after the last administration, the mice were euthanized using intraperitoneal injection of sodium pentobarbital (50 mg/kg). The blood was collected from the punctured heart and the right kidney was stored at -80°C for mRNA and protein extraction.

In study 2, H9c2 cells were assigned to 4 groups.

Group 1 (IgG): Cells received IgG antibody (7 μg/ml, sc-2025, Santa Cruz Biotechnology, USA).

Group 2 (IgG+ISO): Cells received IgG antibody (7 μg/ml) and cultured for 12 h [39]. Subsequently, after adding ISO (10\(^{-5}\) mol/l), cells were cultured for another 48 h [40].

Group 3 (CD47): Cells received CD47 antibody (7 μg/ml, sc-53050, Santa Cruz Biotechnology, USA).

Group 4 (CD47+ISO): Cells received CD47 antibody (7 μg/ml) and cultured for 12 h [39]. Subsequently, after adding ISO (10\(^{-5}\) mol/l), the cells were cultured for another 48 h [40]. CQ was used to inhibit lysosomal acidification and
CD47 antibody in cardiac hypertrophy

autophagosome-lysosome fusion [41]. All experiments were repeated for three times.

**Echocardiography**

The systolic heart function of the mice was evaluated by echocardiography. Briefly, mice were anesthetized with inhalation of 2% isoflurane in the overhead position on a heating pad (40°C). The body temperature of each mouse was monitored and maintained at 37°C throughout the experiments and spontaneous breath was allowed. Echocardiography was performed using a 35-MHz phased-array ultrasound system (Vevo 2100, Visual Sonics Inc., Toronto, Ontario, Canada). To minimize data variation, cardiac function was assessed when the heart rate was within the range of 550-650/minute. Data of 3 consecutive heart cycles in each mouse were digitally recorded and analyzed. The following parameters were measured from M-mode images taken from the parasternal short-axis view at papillary muscle level: interventricular septum (IVS), left ventricular internal dimension (LVID), left ventricular volume (LV vol.), left ventricle mass (LV mass), left ventricular fractional shortening (FS) and left ventricular ejection fraction (EF).

**Biochemical assays**

All blood samples were allowed to clot at room temperature and centrifuged at 2,000 g for 10 min to harvest serum. The biochemical indicators including lactate dehydrogenase (LDH), creatine kinase MB (CK-MB), superoxide dismutase (SOD), malonaldehyde (MDA) were measured spectrophotometrically using commercially available kits for LDH (A020-2), CK-MB (H197), SOD (A001-1), MDA (A003-1) (Jiancheng Bioengineering Institute, Nanjing, China). The heart weight to body weight ratio was calculated by dividing heart weight (mg) by body weight (g).

**Histological and morphometric analysis**

The heart was placed in a 10% potassium chloride solution immediately at end-diastole after removal from the euthanized mice, washed with saline solution, and then placed in 4% paraformaldehyde at 4°C overnight. The heart was transversely cut close to the apex to expose the left and right ventricles. The samples were then dehydrated in an ethanol gradient, rinsed in xylene, and embedded in paraffin. Finally, paraffin blocks were cut into 4 μm sections, stained in H&E for histopathology and Masson for collagen deposition and then visualized by light microscopy. Photos were analyzed using Image-Pro Plus.

**ROS staining**

Total ROS was stained with dihydroethidium (DHE, D-23107; Invitrogen, USA) on fresh frozen sections. The hearts taken out of the euthanized mice were mounted in OCT embedding compound (3801480; Leica, Germany), frozen at -80°C and cut into 5 um thick sections using a cryostat and thawed. The sections were mounted onto gelatin-coated histological slides. 5 uM DHE dissolved in DMSO was added to fresh frozen mouse heart sections after dilution in PBS, incubated in darkness at 37°C for exactly 30 min, and then rinsed twice with cold PBS. The photos were taken immediately.

**Quantitative real time polymerase chain reaction (Q-PCR)**

Total mRNA was extracted from heart samples using TRIzol reagent (B5704-1, Takara, Dalian, China) and then treated with DNase I (2212, Takara, Dalian, China) according to the manufacturer’s protocol. The quality and quantity of RNA were determined using a spectrophotometer (NanoDrop 2000c, Thermo Scientific, USA). cDNA was immediately synthesized using a PrimeScript™ RT Reagent Kit (RR037A, Takara, Dalian, China) according to the manufacturer’s instructions. Q-PCR was performed using a Light Cycler PCR QC Kit (Roche, Switzerland) and a 7300 Real-Time PCR System (LC96, Roche, Switzerland). The primer sequences used were as follows: natriuretic peptide precursor type A (ANP) (NM_008725.3) forward: AAGAGGCGAGTCTATCGGA, reverse: TTGGCTTCCAGGCCATAAGT; brain natriuretic peptide (BNP) (NM_001287348.1) forward: TCTTGTGCCCAAAGCAGCTT, reverse: ATGGATCTCCTGAAGGTGCT; and β-actin (NM_007393.3) forward: CACGGTTGGCCTTAGGGTTCAG, reverse: GCTGTATTCCCCTCCATCGTG. The housekeeping gene β-actin was used as an internal reference. Data analysis was performed and graphs were produced using GraphPad Prism 5 software.
In situ TUNEL staining assay

A terminal deoxynucleotidyltransferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end-labeling (TUNEL) assay was performed according to the manufacturer’s instructions (11684817910, Roche, Switzerland). Heart tissues were fixed in 4% paraformaldehyde overnight, dehydrated, embedded in paraffin, sectioned into 4-μm-thick sections and placed on numbered polylysine-coated glass slides. Deparaffinized tissue sections were incubated with proteinase K (20 mg/ml, Sigma, USA) in a humidified chamber for 15 min, and endogenous peroxidase activity was blocked by a 10-min 3% H₂O₂ treatment. The sections were incubated with TdT labeling buffer at 37°C for 1 h in a moist chamber and then counterstained with DAPI. TUNEL-positive cells showed brown and the nuclei blue. Five random fields per slide (five slides per animal, seven animals per group) were examined. The nuclei number of TUNEL-positive cells (Numerator) and the total number of cellular nuclei (denominator) were counted as previously mentioned [42]. The rate of TUNEL-positive cells in each field was analyzed using Image Pro Plus 6.0 software.

LC3 puncta quantification

The mRFP-GFP-LC3 virus was purchased from Hanbio Biotechnology Co., Ltd. (Shanghai, China), and titers were determined (1×10⁹). H9c2 cells were first transfected with the mRFP-GFP-LC3 virus following the manufacturer’s instructions. After treatment, the cells were fixed with 4% paraformaldehyde. The GFP-LC3 punctate dot structures in individual live H9c2 cells were imaged using a fluorescence microscope. Autophagy was quantified by calculating the percentage of GFP-positive (green) puncta, and upon fusion with lysosomes, the puncta became mRFP-positive (red). The nuclei were counterstained with 4’, 6-Diamidino-2-Phenylindole (DAPI) (Sigma-Aldrich). The images were taken using the Confocal Imaging System (Zeiss LSM710, ZEISS, Germany).

Transmission electron microscopy (TEM)

For TEM examination, H9C2 cells were digested and centrifuged (800× g for 5 min at 25°C) to form cell pellets, fixed in 2.5% glutaraldehyde for 48 h at 4°C, post fixed in 0.5% osmium tetroxide, dehydrated and embedded in epoxy resin. Ultrathin sections (90 nm thick) were made and examined using TEM (Tecnai G2 Spirit Bio TWIN; FEI Ltd.) at accelerating voltage of 80 kV and x10,000 magnification. Electron micrographs (five fields of view per cell) were randomly examined (five cells at four corners and in the middle of the field were selected) for each experiment.

Western blotting

Both cell and tissue proteins were extracted by homogenizing samples in 1× RIPA buffer with 1 mmol/L phenyl methyl sulfonfly fluoride (PMSF) and protease inhibitor cocktail. Protein concentrations were determined using the Coomassie Plus™ Protein Assay reagent. The total protein (30 mg) was separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane. Each membrane was blocked with 5% nonfat milk in TBST buffer (100 mM NaCl, 10 mM Tris-HCl, pH 7.4, 0.1% Tween-20) for 1 h prior to incubation with primary antibodies against LC3 (4108, Cell Signaling Technology, USA), LAMP-2 (sc-71492, Santa Cruz Biotechnology, USA), ATG5 (12994, Cell Signaling Technology, USA), ATG5 (8558, Cell Signaling Technology, USA), Cleaved caspase-3 (9664, Cell Signaling Technology, USA), Cleaved caspase-9 (7237, Cell Signaling Technology, USA) and GAPDH (sc-166574, Santa Cruz Biotechnology, USA). Then, the membranes were washed 3 times in TBST. The blots were imaged using a ChemiDoc XR+ Molecular Imager (Bio-Rad) with Pierce ECL Western Blotting Substrate (32209, Thermo Scientific) and analyzed using image analysis software (ImageJ 1.42). The housekeeping protein GAPDH was used as an internal reference. Western blotting quantification was corrected for GAPDH expression prior to normalization.

Statistical analysis

All assays were independently performed for 3 times. All data were presented as the means ± standard error of the means and statistically analyzed using SPSS software (version 13.0). One-way ANOVAs were used to determine statistical significance, and Bonferroni post hoc
tests were used for further evaluation of the data. A value of $P < 0.05$ was considered statistically significant.

Results

**CD47 antibody inhibited ISO-induced cardiac hypertrophy**

An increase in the heart to body weight ratio in ISO-induced myocardial infarcted mice indicated cardiac hypertrophy [43]. Hematoxylin-eosin (H&E) staining of the hypertrophic heart paraffin sections showed that the mice injected with ISO had eccentric hypertrophy (Figure 1A). Heart weight to body weight ratio (HW/BW) was significantly increased in IgG+ISO group compared with the IgG group ($P < 0.01$, Figure 1B). Importantly, the HW/BW ratio of mice from the CD47+ISO group was significantly lower than those in the IgG+ISO group ($P < 0.05$). The observed increase in the heart weight in ISO-treated mice might be attributed to the elevated water content, oedematous intramuscular space and extensive necrosis of cardiac muscle fibers followed by the invasion of damaged tissues caused by the inflammatory cells [44].

ISO-induced cardiac hypertrophy is associated with increased fibrosis in the myocardium [45]. Cardiac fibrosis is characterized by excessive extracellular matrix accumulation and fibroblast deposition, which can eventually destroy organ architecture and abolish normal cardiac functions [45-47]. In this study, fibrosis detected by Masson’s trichrome staining for collagen was negligible in hearts of mice from the IgG and CD47 groups, whereas fibrosis significantly increased in mice of the IgG+ISO group ($P < 0.01$, Figure 1C, 1D). Compared with the ISO group, fibrosis was significantly lower in mice from the CD47+ISO group ($P < 0.01$).

Pathological hypertrophy and heart failure are accompanied by altered expression of a large number of genes that are correlated with loss of cardiac functions [48]. Hypertrophic genes, natriuretic peptide precursor type A (ANP) and brain natriuretic peptide (BNP) are molecular markers of cardiac hypertrophy [48]. Cardiac expression of hypertrophy-related genes ANP and BNP were detected by Q-PCR (Figure 1E, 1F). The mRNA levels of ANP and BNP were significantly lower than those in the IgG+ISO group ($P < 0.01$), suggesting an inhibitory effect of CD47 antibody on the expression of hypertrophy-related genes.

**CD47 antibody attenuated ISO-induced cardiac dysfunction**

Cytosolic enzymes such as CK-MB and LDH, which serve as the diagnostic markers, leak out from the damaged tissues to blood stream when cell membrane ruptures or becomes permeable [49]. The effects of CD47 antibody on cardiac function index are shown in Figure 1G, 1H. There was no significant difference in LDH and CK-MB levels between the IgG and CD47 groups. ISO treatment in the IgG+ISO group increased LDH and CK-MB levels compared with the control group ($P < 0.01$), CD47 antibody treatment in the CD47+ISO group decreased LDH and CK-MB levels compared with the ISO group ($P < 0.01$).

The echocardiography revealed significant impairment in LV function after ISO infusion, including EF and FS (Figure 2A, 2B). Also, consistent with the H&E results (Figure 1A, 1B), the two-week application of ISO in mice from the IgG+ISO group produced a marked increase in heart size, including interventricular septum (IVS, d), left ventricular volume (LV Vol.), left ventricle mass (LV Mass), compared with the control group ($P < 0.05$ or $P < 0.01$, respectively, Figure 2B). These physiological changes were inhibited by CD47 antibody treatment ($P < 0.05$ or $P < 0.01$).

**CD47 antibody protected against ISO-induced oxidative stress in cardiac tissues**

The effects of CD47 antibody on oxidative stress level in cardiac tissues are shown in Figure 3A, 3B. There was no significant difference in MDA and SOD levels between the IgG and the CD47 groups. ISO treatment in the IgG+ISO group increased MDA level, attenuated SOD activity in cardiac tissues compared with the IgG group ($P < 0.01$). CD47 antibody treatment in the CD47+ISO group decreased MDA levels and promoted SOD activity compared with the ISO group ($P < 0.05$ or $P < 0.01$).

To assess the effects of ISO on ROS production, we visualized intracellular generation of the ROS moiety $O_2^-$ with the fluoroprobe DHE.
Figure 1. CD47 antibody inhibited ISO-induced cardiac hypertrophy. A. Representative H&E staining of mouse hearts from the four groups. B. Heart weight to body weight ratio (HW/BW) was significantly increased after ISO treatment, n=7 per group. C. The levels of fibrosis in the four groups were detected by Masson’s trichrome staining. D. Quantification of the volume of interstitial fibrosis was performed using Image-Pro Plus (n=6). CD47 antibody abolished the effects of ISO in increasing cardiac fibrosis. E, F. Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were increased in the ISO-induced mice which were reversed by CD47 antibody treatment. G, H. CD47 antibody treatment decreased CK-MB and LDH levels induced by ISO, n=7 per group. Data were analyzed by one-way ANOVA followed by Bonferroni’s post-hoc test and expressed as the mean ± SD. Statistical significance: *P < 0.05 and **P < 0.01 versus the IgG group; #P < 0.05 and ##P < 0.01 versus the IgG+ISO group.

staining (Figure 3C). Confocal microscopy showed cardiac tissue sections from the ISO group had a widespread and marked increase in DHE fluorescence compared with those from the IgG group (P < 0.01, Figure 3D). CD47 antibody treatment decreased ROS fluorescence intensity in the CD47+ISO group compared with that in the IgG+ISO group (P < 0.01).
Figure 2. CD47 antibody attenuated ISO-induced cardiac dysfunction. A. Left ventricular (LV) function was measured by echocardiography. B. Echocardiography revealed significant impairment in LV function after ISO infusion, as evidenced by changes in EF; FS; LV mass; IVS, d; and LV vol. CD47 antibody treatment improved cardiac function. Data were analyzed by one-way ANOVA followed by Bonferroni’s post-hoc test and expressed as the mean ± SD, n=7 per group. Statistical significance: *P < 0.05 and **P < 0.01 versus the IgG group; #P < 0.05 and ##P < 0.01 versus the IgG+ISO group.
CD47 antibody in cardiac hypertrophy

Figure 3. CD47 antibody protected against ISO-induced oxidative stress in cardiac tissues. A, B. CD47 antibody treatment increased the SOD activity and decreased the MDA level in serum induced by ISO, n=7 per group. C. The ROS levels in the hearts of mice from all groups were revealed by DHE staining of frozen sections. D. CD47 antibody treatment decreased ROS fluorescence intensity. The fluorescence intensity of DHE staining was analyzed using Image-Pro Plus, n=7 per group. Data were analyzed by one-way ANOVA followed by Bonferroni’s post-hoc test and expressed as the mean ± SD. Statistical significance: *P < 0.05 and **P < 0.01 versus the IgG group; #P < 0.05 and ##P < 0.01 versus the IgG+ISO group.

Figure 4. CD47 antibody protected against ISO-induced myocardial cells apoptosis. A. Apoptosis was analyzed using in situ TUNEL fluorescence staining. The nuclei of TUNEL-positive (apoptotic) cells were stained green. Five random fields per section (five sections per tissue from each mouse) were examined in each experiment. B. CD47 antibody treatment decreased the number of TUNEL-positive cells, n=7 per group. Data were analyzed by one-way ANOVA followed by Bonferroni’s post-hoc test and expressed as the mean ± SD. Statistical significance: *P < 0.05 and **P < 0.01 versus the IgG group; #P < 0.05 and ##P < 0.01 versus the IgG+ISO group.

CD47 antibody protected against ISO-induced cardiomyocyte apoptosis

In the TUNEL assay, the nuclei of the TUNEL-positive (apoptotic) cells were stained green, indicating apoptosis (Figure 4A). There was no significant difference in apoptosis rates between the IgG and the CD47 groups (Figure 4B). The levels of apoptosis were indicated as the percentage of TUNEL-positive cells among total
CD47 antibody in cardiac hypertrophy

Few apoptotic cells were observed in the IgG and the CD47 groups, whereas the IgG+ISO group displayed more TUNEL-positive cells than the IgG and the CD47 groups ($P < 0.01$). As expected, CD47 antibody treatment decreased the number of TUNEL-positive cells significantly, and fewer apoptotic cells were observed in the CD47+ISO group compared with the IgG+ISO group ($P < 0.01$).

**CD47 antibody protected against ISO-induced accumulation of autophagosomes in H9c2 cells**

TEM was performed to detect the accumulation of autophagosomes in H9c2 cells. The results showed no significant difference in apoptotic rates between the IgG and the CD47 groups (Figure 5A, 5B). Compared with the IgG group, ISO treatment increased autophagic vesicle number in the IgG+ISO group ($P < 0.01$). Compared with the IgG+ISO group, CD47 treatment decreased autophagic vesicle number in the CD47+ISO group ($P < 0.01$).

**CD47 antibody protected against ISO-induced cardiac hypertrophy by autophagy activation**

The present study investigated the expression of autophagosomal marker LC3 II, autophagy-associated protein ATG5 and ATG7, autophagosome clearance related protein LAMP2, Cleaved caspase-3 and Cleaved caspase-9 in heart tissues and H9c2 cells using Western blot analysis. As shown in Figures 6A, 6B and S1A, there was no significant difference in protein expression levels of LC3 II, ATG5, ATG7, LAMP2, Cleaved caspase-3 and Cleaved caspase-9 between the IgG and the CD47 groups. ISO treatment in the IgG+ISO group increased LC3 II, ATG5, ATG7 protein levels and decreased LAMP2 protein level compared with the IgG group ($P < 0.01$). CD47 antibody treatment in the CD47+ISO group decreased LC3 II, ATG5, ATG7 protein levels and increased LAMP2 protein level compared with the IgG+ISO group ($P < 0.01$). The expression levels of Cleaved caspase-3 and Cleaved caspase-9 were significantly higher in the IgG+ISO group than the control group ($P < 0.01$). Down-regulation of Cleaved caspase-3 and Cleaved caspase-9 was observed in the CD47+ISO group compared with the IgG+ISO group ($P < 0.01$). However, results shown in Figures 7A, 7B and S1B indicated that chloroquine treatment in the CD47+ISO+CQ group reversed the effect of CD47 treatment in H9c2 cells. Compared with the CD47+ISO group, chloroquine treatment decreased LAMP2 protein level, increased LC3-II and Cleaved caspase-9 protein levels in the CD47+ISO group ($P < 0.05$ or $P < 0.01$, respectively).
CD47 antibody in cardiac hypertrophy

Figure 6. CD47 antibody protected against ISO-induced injury through rescuing impaired autophagy flux. A. Representative Western blots photographs depicting protein levels of LC3 II, LAMP2, ATG5, ATG7, Cleaved caspase-3 and Cleaved caspase 9 in cardiac tissues. The figures were representative images of three different experiments. B. CD47 antibody promoted autophagy flow and inhibited apoptosis. Data were analyzed by one-way ANOVA followed by Bonferroni’s post-hoc test and shown as the mean ± SD, n=7 per group. Statistical significance: *P < 0.05 and **P < 0.01 versus the IgG group, #P < 0.05 and ##P < 0.01 versus the IgG+ISO group, respectively.
CD47 antibody in cardiac hypertrophy

**Discussion**

Cardiac hypertrophy is featured by increased cell size, enhanced protein synthesis, and heightened organization of the sarcomere, and associated with the aggregation of misfolded proteins and damage of sub-cellular organelles including mitochondria, which can be cleared by a bulk degradation autophagic process [4, 7]. Ventricular hypertrophy usually involves decreased autophagy, which facilitates the accumulation of unfolded proteins and worsens cardiac functions, whereas autophagy is enhanced during the regression of hypertrophy [51]. In the present study, ISO-injected mice showed significant elevated serum levels of the described marker enzymes, LDH and CK-MB. This study also showed that HW/BW ratios, cardiac fibrosis and the expressions of hypertrophic genes, ANP and BNP, were significantly increased by ISO treatment; while CD47 antibody reversed these changes. We have thus confirmed that CD47 antibody can exert cardio-protective effects against ISO-induced cardiac hypertrophy by inhibiting heart failure, cardiac fibrosis and cardiac hypertrophy.

ROS is also important for the development of cardiac hypertrophy [52-54]. Various experimental and clinical studies have shown that an enormous number of ROS, such as superoxide, hydrogen peroxide and hydrogen radicals, are generated in failing myocardium [55]. Although a low level of ROS is essential for normal physiological function, excessive ROS produced in dysfunctional mitochondria may be compromised and eventually overwhelmed, which can result in inflammation, apoptosis, heart dysfunction and hypertrophy [56-59]. In the present study, ISO administration resulted in marked decrease in SOD and elevation in MDA and ROS levels, which is in line with the previous reports [55, 60, 61]. CD47 antibody treatment increased serum SOD, while at the same time, decreased serum MDA, a lipid peroxidation index, and ROS level. Thus, the anti-oxidant mechanism should be one pathway through which CD47 antibody protects cardiac functions against ISO-induced myocardial injury.

Autophagy is beneficial to the heart in pressure overload, b-adrenergic stress and other forms of stress. Although the pathogenesis of cardiac hypertrophy is complex and remains to be clarified, emerging evidence has indicated that autophagy, an evolutionarily conserved catabolic pathway, participates in pathological cardiac hypertrophy [8, 62-64]. Several molecular mechanisms, including LC3 II, ATG5, ATG7 and LAMP2, respond to autophagy regulation [65-68]. Therefore, the present study examined the changes in the levels of these autophagy-associated proteins in mice with ISO-induced cardiac hypertrophy. In mammalian cells, LC3 II is produced from LC3 I and modified into a membrane-bound form to prompt its localization to autophagosomes [69]. Thus, LC3 II is considered to be an autophagosomal marker [70].

---

**CD47 antibody protected against ISO-induced cardiac hypertrophy by activating autophagic flux in H9c2 cells**

H9c2 cells were transfected with the mRFP-GFP-LC3 virus for effective and convenient monitoring of autophagic flux (Figure 7C, 7D). Autophagosome induction can result in an increase of green puncta, and the combination of autophagosomes and lysosome can result in an increase of red puncta [50]. The cells in the IgG and the CD47 groups presented diffused and weak green and red dots in cytoplasm compared with the IgG+ISO group. Compared with the IgG group, ISO treatment increased green puncta number in the IgG+ISO group (P < 0.01). Compared with the IgG+ISO group, CD47 treatment decreased autophagosome clearance in the CD47+ISO group (P < 0.01). Compared with the CD47+ISO group, chloroquine treatment in the CD47+ISO+CQ group reversed the effect of CD47 treatment (P < 0.01).

---

**Figure 7.** Blockage of autophagy reversed the protective effect of CD47 antibody on ISO induced H9C2 cells injury. A. Representative Western blots photographs depicting protein levels of LC3 II, LAMP2 and Cleaved caspase 9 in H9c2 cells. The figures were representative images of three different experiments. B. Autophagy inhibitor chloroquine (CQ) treatment reversed the autophagy flow promotion of CD47 antibody in H9c2 cells. The protein expression levels were quantitatively analyzed, n=7 per group. C. Representative images showing the LC3 fluorescent signals in H9c2 cells transfected with mRFP-GFP-LC3. D. LC3 dots in different groups were quantified and presented as bar graphs, n=7 per group. Data were analyzed by one-way ANOVA followed by Bonferroni’s post-hoc test and shown as the mean ± SD. Statistical significance: *P < 0.05 and **P < 0.01 versus the IgG group, #P < 0.05 and ##P < 0.01 versus the IgG+ISO group, &P < 0.05 and &&P < 0.01 versus the CD47+ISO group, respectively.
ATG5 and ATG7, which are required for autophagosome formation and degrade upon autophagosome processing, increased in ISO-treated hearts [22, 26]. In this study, the expression of LC3 II, ATG5 and ATG7 increased significantly and was associated with the reduction of cell apoptosis in ISO-treated hearts, suggesting that excessive activation of autophagy induced by ISO may be detrimental for myocardial cell survival. Clinical studies have also demonstrated that adrenergic blockers significantly improve cardiac functions and reduce cardiac apoptosis in patients with heart failure [71, 72]. Notably, CD47 antibody treatment significantly downregulated the expression of LC3 II, ATG5 and ATG7 and improved the survival rate of the myocardial cells. These results indicated that CD47 antibody promoted cell survival through inhibiting the excessive activation of autophagy induced by ISO.

To further explore the role of CD47 in autophagic flux, we assessed the expression of LAMP2 and the number of autophagosomes in cardiomyocytes. LAMP2 is an important lysosome membrane protein in autophagosome-lysosome fusion [67, 68]. LAMP2 knockdown impairs autophagy in ventricular myocytes of adult rats and causes cell death at levels comparable to autophagy inhibition with 3MA [73]. LAMP2 deficiency [74, 75] caused by mutations in individuals with Danon disease [76], a disease characterized by autophagosome accumulation in multiple tissues including the myocardium [75], can lead to extensive myocardial fibrosis [77]. In this study, we observed a rapid decline in LAMP2 abundance and an increase in the number of autophagosomes in the IgG+ISO group. CD47 antibody treatment was found to improve autophagosome processing by upregulating LAMP2 and decreasing the number of autophagosomes. However, CQ can neutralize the effect of CD47 antibody treatment by inhibiting autophagosome processing. The results suggested that the inhibition of autophagy flux induced autophagosome accumulation, which is an important pathogenic mechanism for cardiac hypertrophy. The activation of autophagic flux by rapamycin has been reported to prevent cardiac hypertrophy induced by thyroid hormone treatment [78, 79]. Pressure overload due to transverse aortic constriction also revealed that autophagic flux decreased during hypertrophic responses [8]. The activation of cardiomyocyte autophagic flux may be a novel therapeutic strategy against cardiac hypertrophy and dysfunction.

In conclusion, these findings demonstrated the protective effect of CD47 antibody against cardiac hypertrophy through improving autophagy flux, rescuing autophagic clearance and improving cardiac performance. CD47 antibody, if further confirmed in vivo, may offer a potential therapeutic approach to prevent cardiac hypertrophy.

Acknowledgements

This study was supported by the Natural Science Foundation of China (No. 81627802).

Disclosure of conflict of interest

None.

Address correspondence to: Xiangqing Kong, Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, P. R. China. E-mail: xiangqing_kong@sina.com; Daorong Hou, Key Laboratory of Model Animal Research, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing 211166, Jiangsu Province, P. R. China. E-mail: houdaorong@njmu.edu.cn

References

CD47 antibody in cardiac hypertrophy


[42] Tang CY, Lai CC, Huang PH, Yang AH, Chiang SC, Huang PC, Tseng KW and Huang CH. Mag-


[77] Maron BJ, Roberts WC, Arad M, Haas TS, Spizio P, Wright GB, Almquist AK, Baffa JM, Saul JP, Ho CY, Seidman J and Seidman CE. Clinical outcome and phenotypic expression in LAMP2
CD47 antibody in cardiac hypertrophy


Figure S1. A, B. Original images of Western blots for Figures 6 and 7.